Therefore, this study offers a rationale for the combination of PD-1/PD-L1 inhibitors with TNFα blockade as a novel immunotherapeutic strategy to overcome resistance in lung cancer, and the phase I clinical trial testing the combination is ongoing (NCT03293784). This evidence concerns the gene CD274 and lung carcinoma.